Form 4: FMR LLC Trims Beam Therapeutics Stake

FMR LLC, a 10% owner of Beam Therapeutics Inc., reported the sale of 459 common shares at $26.68 per share on October 27, 2025.

Summary

• FMR LLC, identified as a 10% owner of Beam Therapeutics Inc. (BEAM), reported a transaction involving its beneficial ownership.
• On October 27, 2025, FMR LLC disposed of 459 shares of Beam Therapeutics Common Stock.
• The shares were sold at a price of $26.68 per share.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
• Following this transaction, FMR LLC indirectly beneficially owns 1,139,443 shares through F-Prime Capital Partners Healthcare Fund V LP.
• FMR LLC also indirectly beneficially owns 841,231 shares through FMR Capital, Inc. after the reported sale.
• The total indirect beneficial ownership by FMR LLC after the transaction is 1,980,674 shares.

Sentiment

Score: 5

Explanation: The sale of 459 shares by FMR LLC, a 10% owner, is a negligible amount relative to their total holdings (over 1.9 million shares) and Beam Therapeutics Inc.'s market capitalization. The transaction was also conducted under a Rule 10b5-1 plan, suggesting it was pre-scheduled and not reactive, leading to a neutral sentiment.

Positives

• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-arranged sale rather than a reactive decision based on immediate company news.

Negatives

• A 10% owner reduced its stake in Beam Therapeutics Inc., although the amount of shares sold (459) is negligible relative to its total holdings and the company's market capitalization.

Risks

• While the sale volume is very small, any reduction in ownership by a significant institutional investor could be theoretically interpreted as a minor signal, though this is highly speculative given the insignificant volume.

Future Outlook

This Form 4 filing reports an insider transaction and does not contain any forward-looking statements or guidance regarding Beam Therapeutics Inc.'s future performance or outlook.

Management Comments

• The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Securities Exchange Act of 1934 or otherwise, the undersigned are the beneficial owners of any securities reported herein.

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or analysis of trends within the biotechnology or gene editing sector.

Related Party Transactions

• FMR LLC's indirect beneficial ownership includes shares held by F-Prime Capital Partners Healthcare Fund V LP and FMR Capital, Inc., which are related entities to FMR LLC.
• Abigail P. Johnson, a Director, Chairman, and Chief Executive Officer of FMR LLC, is part of the Johnson family, who are predominant owners of FMR LLC's Series B voting common shares, forming a controlling group with respect to FMR LLC.

Stakeholder Impact

• Shareholders: The impact on shareholders is minimal due to the extremely small volume of shares sold relative to the company's total outstanding shares and FMR LLC's overall holdings.

Key Dates

Keywords

FMR LLC, Beam Therapeutics, BEAM, Form 4, insider sale, beneficial ownership, 10b5-1 plan, institutional investor